The authors hypothesized that the immune response may be improved by decreasing FGF-23 serum levels with Burosumab treatment, which may reduce the occurrence of dental abscesses, since high FGF-23 serum levels have been shown to correlate with an increased risk of infection [49]. This evidence concerns the gene FGF23 and infection.